FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946220> ?p ?o ?g. }

• W4361946220 abstract "<div>AbstractPurpose:<p>In phase I testing, alisertib tablets with irinotecan and temozolomide showed significant antitumor activity in patients with neuroblastoma. This study sought to confirm activity of this regimen; evaluate an alisertib oral solution; and evaluate biomarkers of clinical outcomes.</p>Patients and Methods:<p>We conducted a two-stage phase II trial of alisertib tablets (60 mg/m²/dose × 7 days), irinotecan (50 mg/m²/dose i.v. × 5 days), and temozolomide (100 mg/m²/dose orally × 5 days) in patients with relapsed or refractory neuroblastoma. The primary endpoint was best objective response. A separate cohort was treated with alisertib at 45 mg/m² using oral solution instead of tablets. Exploratory analyses sought to identify predictors of toxicity, response, and progression-free survival (PFS) using pooled data from phase I, phase II, and oral solution cohorts.</p>Results:<p>Twenty and 12 eligible patients were treated in the phase II and oral solution cohorts, respectively. Hematologic toxicities were the most common adverse events. In phase II, partial responses were observed in 19 evaluable patients (21%). The estimated PFS at 1 year was 34%. In the oral solution cohort, 3 patients (25%) had first cycle dose-limiting toxicity (DLT). Alisertib oral solution at 45 mg/m² had significantly higher median <i>C</i>_max and exposure compared with tablets at 60 mg/m². Higher alisertib trough concentration was associated with first cycle DLT, whereas <i>MYCN</i> amplification was associated with inferior PFS.</p>Conclusions:<p>This combination shows antitumor activity, particularly in patients with <i>MYCN</i> nonamplified tumors. Data on an alisertib oral solution expand the population able to be treated with this agent.</p></div>" @default.
• W4361946220 created "2023-04-05" @default.
• W4361946220 creator A5000283082 @default.
• W4361946220 creator A5001066329 @default.
• W4361946220 creator A5005528190 @default.
• W4361946220 creator A5005797590 @default.
• W4361946220 creator A5010848347 @default.
• W4361946220 creator A5015572385 @default.
• W4361946220 creator A5017501517 @default.
• W4361946220 creator A5017840054 @default.
• W4361946220 creator A5018934758 @default.
• W4361946220 creator A5020759638 @default.
• W4361946220 creator A5027416118 @default.
• W4361946220 creator A5030496565 @default.
• W4361946220 creator A5032778724 @default.
• W4361946220 creator A5034629778 @default.
• W4361946220 creator A5035030496 @default.
• W4361946220 creator A5036062620 @default.
• W4361946220 creator A5038815138 @default.
• W4361946220 creator A5040815350 @default.
• W4361946220 creator A5046269837 @default.
• W4361946220 creator A5057328309 @default.
• W4361946220 creator A5057493583 @default.
• W4361946220 creator A5058782198 @default.
• W4361946220 creator A5061278042 @default.
• W4361946220 creator A5062167990 @default.
• W4361946220 creator A5067387322 @default.
• W4361946220 creator A5071788335 @default.
• W4361946220 creator A5072874640 @default.
• W4361946220 creator A5078500931 @default.
• W4361946220 creator A5091337917 @default.
• W4361946220 date "2023-03-31" @default.
• W4361946220 modified "2023-09-26" @default.
• W4361946220 title "Data from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma" @default.
• W4361946220 doi "https://doi.org/10.1158/1078-0432.c.6527279" @default.
• W4361946220 hasPublicationYear "2023" @default.
• W4361946220 type Work @default.
• W4361946220 citedByCount "0" @default.
• W4361946220 crossrefType "posted-content" @default.
• W4361946220 hasAuthorship W4361946220A5000283082 @default.
• W4361946220 hasAuthorship W4361946220A5001066329 @default.
• W4361946220 hasAuthorship W4361946220A5005528190 @default.
• W4361946220 hasAuthorship W4361946220A5005797590 @default.
• W4361946220 hasAuthorship W4361946220A5010848347 @default.
• W4361946220 hasAuthorship W4361946220A5015572385 @default.
• W4361946220 hasAuthorship W4361946220A5017501517 @default.
• W4361946220 hasAuthorship W4361946220A5017840054 @default.
• W4361946220 hasAuthorship W4361946220A5018934758 @default.
• W4361946220 hasAuthorship W4361946220A5020759638 @default.
• W4361946220 hasAuthorship W4361946220A5027416118 @default.
• W4361946220 hasAuthorship W4361946220A5030496565 @default.
• W4361946220 hasAuthorship W4361946220A5032778724 @default.
• W4361946220 hasAuthorship W4361946220A5034629778 @default.
• W4361946220 hasAuthorship W4361946220A5035030496 @default.
• W4361946220 hasAuthorship W4361946220A5036062620 @default.
• W4361946220 hasAuthorship W4361946220A5038815138 @default.
• W4361946220 hasAuthorship W4361946220A5040815350 @default.
• W4361946220 hasAuthorship W4361946220A5046269837 @default.
• W4361946220 hasAuthorship W4361946220A5057328309 @default.
• W4361946220 hasAuthorship W4361946220A5057493583 @default.
• W4361946220 hasAuthorship W4361946220A5058782198 @default.
• W4361946220 hasAuthorship W4361946220A5061278042 @default.
• W4361946220 hasAuthorship W4361946220A5062167990 @default.
• W4361946220 hasAuthorship W4361946220A5067387322 @default.
• W4361946220 hasAuthorship W4361946220A5071788335 @default.
• W4361946220 hasAuthorship W4361946220A5072874640 @default.
• W4361946220 hasAuthorship W4361946220A5078500931 @default.
• W4361946220 hasAuthorship W4361946220A5091337917 @default.
• W4361946220 hasConcept C121332964 @default.
• W4361946220 hasConcept C121608353 @default.
• W4361946220 hasConcept C126322002 @default.
• W4361946220 hasConcept C142424586 @default.
• W4361946220 hasConcept C197934379 @default.
• W4361946220 hasConcept C2777389519 @default.
• W4361946220 hasConcept C2780259306 @default.
• W4361946220 hasConcept C2781413609 @default.
• W4361946220 hasConcept C29730261 @default.
• W4361946220 hasConcept C31760486 @default.
• W4361946220 hasConcept C509974204 @default.
• W4361946220 hasConcept C526805850 @default.
• W4361946220 hasConcept C71924100 @default.
• W4361946220 hasConcept C87355193 @default.
• W4361946220 hasConcept C90924648 @default.
• W4361946220 hasConceptScore W4361946220C121332964 @default.
• W4361946220 hasConceptScore W4361946220C121608353 @default.
• W4361946220 hasConceptScore W4361946220C126322002 @default.
• W4361946220 hasConceptScore W4361946220C142424586 @default.
• W4361946220 hasConceptScore W4361946220C197934379 @default.
• W4361946220 hasConceptScore W4361946220C2777389519 @default.
• W4361946220 hasConceptScore W4361946220C2780259306 @default.
• W4361946220 hasConceptScore W4361946220C2781413609 @default.
• W4361946220 hasConceptScore W4361946220C29730261 @default.
• W4361946220 hasConceptScore W4361946220C31760486 @default.
• W4361946220 hasConceptScore W4361946220C509974204 @default.
• W4361946220 hasConceptScore W4361946220C526805850 @default.
• W4361946220 hasConceptScore W4361946220C71924100 @default.
• W4361946220 hasConceptScore W4361946220C87355193 @default.
• W4361946220 hasConceptScore W4361946220C90924648 @default.
• W4361946220 hasLocation W43619462201 @default.
• W4361946220 hasOpenAccess W4361946220 @default.

• next